BioSpace News Archive

The U.S. Advanced Wound Care Market generated $3.35 billion in 2019, and is estimated to reach $4.96 billion by 2027, registering a CAGR of 9.9% from 2020 to 2027.

Today, Avidity Science announces another significant step in expanding its global leadership in biomedical research solutions via the acquisition of UMG, Inc.

OnKure, Inc., a clinical-stage biopharmaceutical company pioneering a novel Class-1 selective histone deacetylase inhibitor for the treatment of solid tumor cancers, announced the appointment of James Winkler, Ph.D. and Duncan Walker, Ph.D. as Chief Scientific Officer and Chief Development Officer, respectively.

Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF at the 2021 Heart Rhythm Society Annual Meeting.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will attend investor meetings at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Global Blood Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2021 and recent business progress.

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that Adrian Adams, chief executive officer, will present on a panel titled “For Headaches THIS Big – The Evolution of Migraine Therapeutic Landscape” at the 2021 Wedbush Pacgrow Virtual Healthcare Conference

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 95,000 shares of Akebia’s common stock on July 30, 2021, as inducements material to each such employee’s entering into employment with Akebia.

Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,125,000 shares of Class A common stock,

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Melinda Litherland to its board of directors.